Q2: Volumes up, prices down—the wait continues

What happened

Novo Nordisk’s Q2 adjusted sales grew 7% at constant exchange rates, driven by GLP-1 volume gains in obesity and diabetes, but lower realized prices and higher manufacturing costs compressed margins. Oral Wegovy demand remained explosive with over 5 million cumulative prescriptions and weekly scripts above 265,000, yet injectable Wegovy sales fell 22% as price erosion more than offset volume. Management lifted full-year adjusted sales guidance to 0% to -6%, reflecting better volume expectations but still deep pricing headwinds. The stock remains cheap at 11x earnings, but the unresolved question is whether unit growth can outrun the 2027 list-price reset and ongoing competitive pressure from Lilly. Investors get another read at the September Capital Markets Day and Q3 results in November, which must show obesity revenue re-acceleration to justify a higher multiple.

Implication

The quarter reinforces that Novo is trading volume for price, and the payoff window is narrow. Oral Wegovy adds new patients, but combined obesity revenue grew only mid-single digits, meaning gross-to-net pressure is still rising. The 2027 list-price cut looms, and unless Q3 shows insured-channel mix improvement and a step-up in total obesity sales, the bull case remains speculative. We maintain the WAIT rating; aggressive buyers should wait for evidence that price pressure is stabilizing before acting.

Thesis delta

No fundamental shift; the Q2 update matches our base case of strong volume but weak price realization. The raised guidance is encouraging but still implies negative growth, and the key catalysts (Capital Markets Day, Q3, 2027 price reset) are unchanged. The thesis remains a balanced ‘show-me’ story.